MX2021000740A - Composiciones y metodos para el tratamiento del cancer. - Google Patents

Composiciones y metodos para el tratamiento del cancer.

Info

Publication number
MX2021000740A
MX2021000740A MX2021000740A MX2021000740A MX2021000740A MX 2021000740 A MX2021000740 A MX 2021000740A MX 2021000740 A MX2021000740 A MX 2021000740A MX 2021000740 A MX2021000740 A MX 2021000740A MX 2021000740 A MX2021000740 A MX 2021000740A
Authority
MX
Mexico
Prior art keywords
compositions
cancer
treatment
methods
formulated
Prior art date
Application number
MX2021000740A
Other languages
English (en)
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of MX2021000740A publication Critical patent/MX2021000740A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones y compuestos de la fórmula I y fórmula II, incluyendo conjugados inhibidores de la síntesis de ácidos nucleicos, o sus polimorfos, enantiómeros, estereoisómeros, solvatos e hidratos de los mismos. Estos conjugados pueden formularse como composiciones farmacéuticas. Las composiciones farmacéuticas pueden formularse para su administración oral, administración intravenosa, en solución, jarabe, sobre, transdérmica o inyección. Estas composiciones pueden utilizarse para el tratamiento del cáncer o de sus complicaciones asociadas.
MX2021000740A 2018-08-03 2019-07-09 Composiciones y metodos para el tratamiento del cancer. MX2021000740A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841029367 2018-08-03
PCT/IB2019/055827 WO2020026054A1 (en) 2018-08-03 2019-07-09 Compositions and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2021000740A true MX2021000740A (es) 2021-03-26

Family

ID=69231514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000740A MX2021000740A (es) 2018-08-03 2019-07-09 Composiciones y metodos para el tratamiento del cancer.

Country Status (11)

Country Link
US (1) US20210171564A1 (es)
EP (1) EP3817732A4 (es)
JP (1) JP2021534085A (es)
KR (1) KR20210057025A (es)
AU (1) AU2019313484A1 (es)
BR (1) BR112021001652A2 (es)
CA (1) CA3108362A1 (es)
IL (1) IL280262A (es)
MX (1) MX2021000740A (es)
SG (1) SG11202100411TA (es)
WO (1) WO2020026054A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022049462A1 (en) * 2020-09-05 2022-03-10 Cellix Bio Private Limited Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU2001278804A1 (en) * 2000-08-09 2002-02-18 Kolon Industries, Inc. 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
ATE405573T1 (de) * 2004-12-17 2008-09-15 Lilly Co Eli Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
US20080262215A1 (en) * 2007-04-23 2008-10-23 Chemagis Ltd. Gemcitabine production process
ME02254B (me) * 2009-01-23 2015-12-31 Euro Celtique Sa Derivati hidroksamske kiseline
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
CA3027118C (en) * 2016-06-28 2023-08-15 Cellix Bio Private Limited Compositions and methods for the treatment of cancer

Also Published As

Publication number Publication date
KR20210057025A (ko) 2021-05-20
CA3108362A1 (en) 2020-02-06
BR112021001652A2 (pt) 2021-05-04
EP3817732A4 (en) 2022-06-08
IL280262A (en) 2021-03-01
AU2019313484A1 (en) 2021-02-18
SG11202100411TA (en) 2021-02-25
AU2019313484A2 (en) 2021-02-25
WO2020026054A1 (en) 2020-02-06
US20210171564A1 (en) 2021-06-10
EP3817732A1 (en) 2021-05-12
JP2021534085A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
PH12017502331A1 (en) 1,4-substituted piperidine derivatives
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
MX2015012427A (es) Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
GEP20166484B (en) Protein kinase inhibitors
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
MX2018009870A (es) Inhibidores de taf1 para la terapia del cancer.
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2020007152A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.
MX2019006920A (es) Derivados de la espiropiperidina.
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2019000279A (es) Composiciones y metodos para el tratamiento del cancer.
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
MX2021000740A (es) Composiciones y metodos para el tratamiento del cancer.
PH12021550258A1 (en) Cdk8/19 inhibitors
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
MX2019005568A (es) Composiciones y metodos para el tratamiento de polipos gastrointestinales.
MX2019004822A (es) Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders